Annexon
Market cap $662M 190.8M shares (vendor count, Nov 18, 2026) × $3.47 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page
Most recent annual filing: 2026-03-15
- ANX1502 C1 readout2026ANX1502 C1 readout, 2026, notable
- ANX1502 POC readout2H 2026ANX1502 POC readout, 2H 2026, notable
- Tanruprubart BLA filing4Q 2026Tanruprubart BLA filing, 4Q 2026, material
- Vonaprument Ph3 topline1Q 2027Vonaprument Ph3 topline, 1Q 2027, thesis-defining
- loan covenant trial startMar 31, 2027loan covenant trial start, Mar 31, 2027, routine
- loan tranche corporate updateSep 30, 2027loan tranche corporate update, Sep 30, 2027, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
Technology platforms
C1q Platform
Upstream classical complement inhibition platform targeting C1q, the initiating molecule of the classical complement pathway; focus areas include neuroinflammatory and autoimmune diseases such as Guillain-Barré syndrome, geographic atrophy, and generalized myasthenia gravis
Targets: C1q
Capital (as filed)
- Cash
- $102M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $111M Sep 30, 2026
- Operating cash flow
- −$48.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $213M cash, runway into 2028 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (7)
- 2026-11-10 UPDATE: Annexon (ANNX) - Q3 Status Check: One Option Fizzles, the Binary Holds 🔒 Paid
- 2026-08-13 UPDATE: Annexon (ANNX) - The Binary Just Grew a Second Half 🔒 Paid
- 2026-08-07 UPDATE: Annexon (ANNX) - The Silent Killer Gets Its First Western Data 🔒 Paid
- 2026-07-30 UPDATE: Annexon (ANNX) - The Dilution Gun Gets a Debt Silencer 🔒 Paid
- 2026-05-08 UPDATE: Annexon (ANNX) - The Dilution Gun Has Fired 🔒 Paid
- 2026-04-04 UPDATE: Annexon (ANNX) - Spring Cleaning, Shelf Registrations, and the Dilution Gap 🔒 Paid
- 2026-02-27 Annexon (ANNX): Scientific Deep Dive for ANX007 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (7 calls)
Every verdict Biotech Distilled has published on Annexon, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-02-27 Watch Annexon (ANNX): Scientific Deep Dive for ANX007 and Pipeline Products Elegant C1q biology but regulatory gambles on functional endpoints and ex-US data justify watching for a better entry ahead of the binary 2H 2026 GA readout.
- 2026-04-04 Watch UPDATE: Annexon (ANNX) - Spring Cleaning, Shelf Registrations, and the Dilution Gap Newly filed S-3 shelf registration reintroduces dilution risk, warranting continued caution despite unchanged science.
- 2026-05-08 Watch UPDATE: Annexon (ANNX) - The Dilution Gun Has Fired ATM has already fired with $32.7M in Q1 sales and shelf upsized to $150M; GBS FDA pushback more explicit, but science and ARCHER II binary unchanged.
- 2026-07-30 Watch UPDATE: Annexon (ANNX) - The Dilution Gun Gets a Debt Silencer Oxford $200M debt facility reduces near-term dilution but concentrates downside risk; binary ARCHER II still dominates and GBS regulatory path remains murky.
- 2026-08-07 Watch UPDATE: Annexon (ANNX) - The Silent Killer Gets Its First Western Data FORWARD n=10 Western data is encouraging for GBS bridging but does not change the ARCHER II binary dominating equity value.
- 2026-08-13 Watch UPDATE: Annexon (ANNX) - The Binary Just Grew a Second Half ARCHER II adds Month 24 dual primary endpoint; Q4 2026 now delivers a DMC verdict rather than a dataset, diffusing the catalyst across multiple quarters while science remains intact.
- 2026-11-10 Watch UPDATE: Annexon (ANNX) - Q3 Status Check: One Option Fizzles, the Binary Holds ANX1502 sidelined to formulation lab and GBS BLA still needs FDA alignment, but ARCHER II trial execution remains clean and balance sheet is adequate into 2028.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (10 quotes from 6 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“We plan to engage with the FDA with the goal of reaching alignment on our submission of a biologics license application, or BLA, anticipated in the fourth quarter of 2026.”
matched to Tanruprubart (ANX005) · regulatory submission
-
-
-
“Next Milestone: EMA review of MAA underway; BLA submission with U.S./European data from FORWARD expected fourth quarter of 2026.”
matched to Tanruprubart (ANX005) · regulatory submission -
“An independent Data Monitoring Committee (DMC) will assess the ARCHER II single study Month 15 primary endpoint in the fourth quarter of 2026.”
matched to Vonaprument (ANX007) · topline data
-
-
-
“Dosing is complete and we plan to provide an update on the POC study in the second half of 2026.”
matched to ANX1502 · readout other -
“The Month 15 primary endpoint remains on track for the fourth quarter of 2026.”
matched to Vonaprument (ANX007) · topline data
-
-
-
“Topline results from the Month 15 primary analysis are expected in the fourth quarter of 2026.”
matched to Vonaprument (ANX007) · topline data
-
-
-
“Next Milestone: Biologics License Application (BLA) submission with U.S./European data from FORWARD trial expected in fourth quarter of 2026.”
matched to Tanruprubart (ANX005) · regulatory submission
-
-
-
“Dosing is complete and we plan to provide an update on the POC study in the second half of 2026.”
matched to ANX1502 · readout other -
“The Month 15 primary endpoint remains on track for the fourth quarter of 2026.”
matched to Vonaprument (ANX007) · topline data -
“Topline results from the Month 15 primary analysis are expected in the fourth quarter of 2026.”
matched to Vonaprument (ANX007) · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (27)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 9, 2026ReleaseAnnexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones→ BD updateSummary on the 8-K
- Nov 9, 20268-KCurrent report: results of operations · EX-99.1→ BD updateWith the ARCHER II DMC verdict weeks away, the Q3 filing reveals the strongest trial-execution metrics yet — 90% patient retention, all eligible patients past the 15-month mark, vision-loss events on track — while ANX1502 hit a formulation wall in CAD and Annexon quietly hired the former IZERVAY commercial lead to run the vonaprument franchise.
- Nov 9, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 28, 2026ReleaseAnnexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial
- Sep 24, 2026ReleaseAnnexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
- Sep 2, 2026ReleaseAnnexon to Participate in Upcoming September Investor Conferences
- Aug 12, 2026ReleaseAnnexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
- Aug 12, 2026ReleaseAnnexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated MilestonesBD extracted 3 program updates from this document → ANNX pipeline
- Aug 12, 20268-KCurrent report: results of operations, other events · EX-99.1BD extracted 1 program update from this document → ANNX pipeline
- Aug 12, 202610-QQuarterly report
- Aug 10, 2026ReleaseAnnexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
- Aug 10, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
- Aug 6, 2026ReleaseAnnexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
- Aug 6, 20268-KCurrent report: other events · EX-99.1BD extracted 1 program update from this document → ANNX pipeline
- Jul 30, 2026ReleaseAnnexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
- Jul 30, 20268-KCurrent report: material agreement, debt / obligation, other events · EX-99.1
- Jul 14, 2026ReleaseAnnexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026BD extracted 1 program update from this document → ANNX pipeline
- Jun 12, 20268-KCurrent report: shareholder vote
- May 27, 2026ReleaseAnnexon to Participate in Upcoming June Investor Conferences
- May 7, 2026ReleaseAnnexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
- May 7, 20268-KCurrent report: results of operations · EX-99.1
- May 7, 202610-QQuarterly report
- Apr 27, 2026DEFA14AProxy soliciting material
- Apr 27, 2026DEF 14AProxy statement
- Mar 31, 2026S-3ASRAutomatic shelf registration
- Mar 30, 20268-KCurrent report: results of operations · EX-99.1
- Mar 30, 202610-KAnnual report
11 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 5, 2026SCHEDULE 13G/A13G amendment
- Aug 7, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 27, 2026SCHEDULE 13G/A13G amendment
- Jul 8, 2026SCHEDULE 13G/A13G amendment
- Jul 8, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- Apr 27, 2026ARSAnnual report to shareholders
- Apr 16, 2026PRE 14APRE 14A
- Mar 31, 2026S-8Employee plan registration
- Mar 26, 2026SCHEDULE 13G/A13G amendment